Supplementation of omega-3 fatty acids in patients with ankylosing spondylitis
Sundstrom B, Stalnacke K, Hagfors L, Johansson G
Published in Scandinavian Journal of Rheumatology
Methodology
Randomised trial comparing high-dose (4.55 g/day) with low-dose (1.95 g/day) omega-3 supplementation for 21 weeks in ankylosing spondylitis.
Key Findings
The high-dose group showed a significant reduction in BASDAI disease activity scores compared with the low-dose group.
Conclusions
High-dose omega-3 fatty acids may modestly reduce disease activity in ankylosing spondylitis, but no placebo arm was included.
Limitations
No placebo control; small sample; single centre; short duration.
Supplements Studied
High-dose omega-3 supplementation significantly reduced BASDAI disease activity versus low dose in ankylosing spondylitis.
Outcomes Measured
High-dose omega-3 supplementation reduced BASDAI disease activity compared with low dose.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.